NuLife Sciences, Inc.

Company Overview

NuLife Sciences is a biomedical company focused on medical research and technology that has the potential to address significant unmet medical needs in applications including transplantation/regenerative medicine/cell therapy/organ and tissue transplants. Through its wholly-owned subsidiary NuLife BioMed, it is currently working on advancing human organ transplant technology based upon a patent protected and unique proprietary method ("NuLife Technique") that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs. With a massive need and market for organ transplants, and over 123K candidates waiting for an organ in the U.S. alone, NuLife's versatile technique is suitable for a variety of clinical indications. The Company has completed discovery phase for its technique, and is now entering a Preclinical phase involving animal experiments on its pathway to commercialization.

Investor Relations Overview

Latest Financial Results

Q1 2017

Quarter Ended Dec 31, 2016

Latest 10-K

For Fiscal Year 2016

Download 10-K

Stock Information

Symbol

OTCQB: NULF

Price

Change

Volume

52 week Low/High

Day Low/High

Contact Information

Investor Relations

MZ Group
Ted Haberfield
President - MZ North America
T: 760-755-2716
M: 858-204-5055
thaberfield@mzgroup.us
www.mzgroup.us

Transfer Agent

Direct Transfer, LLC.
500 Perimeter Park Drive
Suite D
Morrisville, NC 27560
T: 918-481-4000
ts@issuerdirect.com
www.issuerdirect.com